No CrossRef data available.
Article contents
Progress: Measuring the Benefit
Published online by Cambridge University Press: 02 December 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0317167100005102/resource/name/firstPage-S0317167100005102a.jpg)
- Type
- Letters to the Editor
- Information
- Copyright
- Copyright © The Canadian Journal of Neurological 2006
References
1.
Bussière, M, Wiebe, S. The numbers needed to treat for neurological disorders. Can J Neurol Sci. 2005; 32: 440–9.CrossRefGoogle ScholarPubMed
2.
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with a previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033–41.Google Scholar
3.
Wennberg, R, Zimmermann, C.
The PROGRESS trial three years later: time for a balanced report of effectiveness. BMJ. 2004; 329: 968–70.Google Scholar
4.
Wennberg, R, Zimmermann, C.
Perindopril monotherapy and PROGRESS in Europe. BMJ. 2005; 331: 235–6.CrossRefGoogle ScholarPubMed